We are committed to partnering with you to support all affected patients. We have continued to make progress on the remediation of CPAP and BiPAP devices and are asking customers and clinicians to help us to remind patients that they may need to take a specific action in the Patient Portal to receive their replacement device.
While we've made progress with CPAP and BiPAP devices, we remain on a separate remediation timeline for ventilation devices.
Philips Respironics has restarted remediation of Trilogy 100/200 devices in some markets. We will partner with Durable Medical Equipment providers (DMEs) to complete remediation as quickly as possible to address patients on affected Trilogy 100/200 devices. Please visit our ventilation news and updates page for the latest information.
Globally, we have remediated 99% of actionable* sleep therapy device registrations to date.
Continuing to remediate new and existing registrations remains our priority. We will make multiple attempts to ensure we have the information needed to place an order, and will provide responding patients with remediation options.
*Actionable registrations are those that contain the necessary information needed to complete the remediation and are not awaiting patient or DME action.
October 6, 2023
September 27, 2023
Philips Respironics completed the analyses for System One and DreamStation Go sleep therapy devices indicating that the volatile organic compounds (VOCs) and the particulate matter (PM) emissions related to foam degradation are within the appliable safety limits. Additional visual assessments have been performed and confirm the low prevalence of significant foam degradation.
You are about to visit a Philips global content page
Continue